MHC
LBRX

Meyer Handelman Company’s LB Pharmaceuticals LBRX Stock Holding History

Meyer Handelman Company’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Buy
+15,094
New +$348K 0.01% 190

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Meyer Handelman Company's LBRX Position: Q1 2026 in Review

Meyer Handelman Company opened a new position in LB Pharmaceuticals (LBRX) in Q1 2026: 15,094 shares worth $372K. The stake represents 0.01% of the portfolio and ranks #190 among its holdings.

77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Meyer Handelman Company held 15,094 shares of LB Pharmaceuticals worth $372K as of Q1 2026.
  • LB Pharmaceuticals was a new Meyer Handelman Company position in Q1 2026.
  • LB Pharmaceuticals made up 0.01% of Meyer Handelman Company's portfolio in Q1 2026, its #190 holding.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Meyer Handelman Company's 13F filing for Q1 2026, filed 20 Apr 2026.